BPMC News and Press, Blueprint Medicines Corporation From 04/29/24

2024-04-29 07:00:00 ET Summary Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rigel Pharmaceuticals faces both strengths and ris...

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and w...

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics PR Newswire ­ -- Dr. Mariana Castells , M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members ...

2024-04-10 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-29 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable...

2024-02-20 12:17:26 ET Summary Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn r...

Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) traded at a new 52-week high today and are currently trading at $90.05. So far today, approximately 436.14k shares have been exchanged, as compared to an average 30-day volume of 872.33k shares. Blueprint Medicines Corporation, a precis...

2024-02-15 13:11:04 ET Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Conference Call February 15, 2024 08:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commerci...

2024-02-15 07:10:28 ET More on Blueprint Medicines Blueprint Medicines: Looking Toppy Blueprint Medicines Q4 2023 Earnings Preview Barron’s cites cancer and weight loss plays for biotech M&A Seeking Alpha’s Quant Rating on Blueprint Medicine...